[go: up one dir, main page]

MX2007005581A - Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente. - Google Patents

Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente.

Info

Publication number
MX2007005581A
MX2007005581A MX2007005581A MX2007005581A MX2007005581A MX 2007005581 A MX2007005581 A MX 2007005581A MX 2007005581 A MX2007005581 A MX 2007005581A MX 2007005581 A MX2007005581 A MX 2007005581A MX 2007005581 A MX2007005581 A MX 2007005581A
Authority
MX
Mexico
Prior art keywords
temozolomide
patient
dosing regimen
improved dosing
treating cancer
Prior art date
Application number
MX2007005581A
Other languages
English (en)
Inventor
Chen Zong
Benjamin Winograd
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36168622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007005581(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2007005581A publication Critical patent/MX2007005581A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describe el uso de temozolomida para la elaboracion de un medicamento para el tratamiento del cancer en un paciente en necesidad de tal tratamiento, que comprende administrar temozolomida de acuerdo con un regimen y/o programas de dosificacion mejorados, basandose en el nivel de MGMT del paciente, tambien se describen regimenes y/o programas de dosificacion mejorados adicionales para tratar a pacientes con temozolomida.
MX2007005581A 2004-11-09 2005-11-07 Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente. MX2007005581A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62625804P 2004-11-09 2004-11-09
PCT/US2005/040449 WO2006052976A2 (en) 2004-11-09 2005-11-07 Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level

Publications (1)

Publication Number Publication Date
MX2007005581A true MX2007005581A (es) 2007-05-23

Family

ID=36168622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005581A MX2007005581A (es) 2004-11-09 2005-11-07 Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente.

Country Status (13)

Country Link
US (2) US20060100188A1 (es)
EP (1) EP1830845A2 (es)
JP (2) JP2008519584A (es)
CN (1) CN101098696A (es)
AU (1) AU2005304672B2 (es)
BR (1) BRPI0517976A (es)
CA (1) CA2585446A1 (es)
MX (1) MX2007005581A (es)
NO (1) NO20072931L (es)
NZ (1) NZ554831A (es)
TW (1) TW200630089A (es)
WO (1) WO2006052976A2 (es)
ZA (1) ZA200703716B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038535A1 (es) * 2002-02-22 2005-01-19 Schering Corp Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
JP2008519584A (ja) * 2004-11-09 2008-06-12 シェーリング コーポレイション 患者のｍｇｍｔレベルに基づいて癌を処置するための、テモゾロミドの改良された投薬養生法
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
CN101370497B (zh) * 2006-01-17 2010-11-17 雅培制药有限公司 包含parp抑制剂和细胞毒性剂的联合产品及用途
EP2997964A1 (en) 2006-04-05 2016-03-23 OPKO Health, Inc. Pharmaceutical formulations comprising salts of (5s,8s)-8-[{(1 r)-1-(3,5-bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one and their medical use
WO2007117486A2 (en) 2006-04-05 2007-10-18 Schering Corporation Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
US20070264672A1 (en) * 2006-05-09 2007-11-15 Bimalendu Dasmahapatra Development of a novel assay for mgmt (methyl guanine methyl transferase)
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
US20100210700A1 (en) 2007-05-08 2010-08-19 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
MX377267B (es) * 2013-04-17 2025-03-07 Signal Pharm Llc Tratamiento de cáncer con dihidropirazino-pirazinas.
WO2016164916A1 (en) 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
CN110408694A (zh) * 2018-04-26 2019-11-05 胤安国际（辽宁）基因科技股份有限公司 评估替莫唑胺在治疗脑胶质瘤患者的敏感性的新方法
US20220195440A1 (en) * 2019-03-28 2022-06-23 Thomas Jefferson University Methods for treating cancers using antisense
WO2023113538A1 (ko) * 2021-12-17 2023-06-22 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법
CN119318654A (zh) * 2024-12-16 2025-01-17 中国医学科学院基础医学研究所 氟达拉滨和替莫唑胺联用在治疗脑胶质瘤中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5876146A (en) * 1995-10-27 1999-03-02 General Electric Company Apparatus and methods for repairing jet pump diffusers in a nuclear reactor
US5786146A (en) * 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) * 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
DK1165071T3 (da) * 1999-03-30 2006-02-20 Schering Corp Forbedret cancerbehandling med temozolomid
US6346524B1 (en) * 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide
WO2001085221A2 (en) * 2000-05-12 2001-11-15 Duke University Assessing levels of o6-alkylguanine-dna alkyltransferase in vivo
US6773897B2 (en) * 2000-09-29 2004-08-10 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
WO2002103013A2 (en) * 2000-10-30 2002-12-27 Gene Logic, Inc. Partially double-stranded nucleic acids, methods of making, and use thereof
CA2429437A1 (en) * 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Imidazole derivatives, process for their preparation and their use
EP1556700A2 (en) * 2002-10-28 2005-07-27 Pharmacia Italia S.p.A. Method for optimizing therapeutic efficacy of nemorubicin
WO2004086949A2 (en) * 2003-03-25 2004-10-14 John Wayne Cancer Institute Dna markers for management of cancer
JP2008519584A (ja) * 2004-11-09 2008-06-12 シェーリング コーポレイション 患者のｍｇｍｔレベルに基づいて癌を処置するための、テモゾロミドの改良された投薬養生法
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule

Also Published As

Publication number Publication date
TW200630089A (en) 2006-09-01
AU2005304672A1 (en) 2006-05-18
WO2006052976A2 (en) 2006-05-18
WO2006052976A3 (en) 2006-08-17
CN101098696A (zh) 2008-01-02
BRPI0517976A (pt) 2008-10-21
CA2585446A1 (en) 2006-05-18
JP2008519584A (ja) 2008-06-12
US20090247598A1 (en) 2009-10-01
AU2005304672B2 (en) 2010-03-11
NO20072931L (no) 2007-08-03
NZ554831A (en) 2009-10-30
JP2011121960A (ja) 2011-06-23
EP1830845A2 (en) 2007-09-12
US20060100188A1 (en) 2006-05-11
ZA200703716B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
MX2007005581A (es) Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente.
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
NZ544472A (en) Compounds and therapeutical use thereof
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
LU92692I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptablede celui-ci
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
WO2004064734A3 (en) Combination therapies for the treatment of cancer
IL182352A0 (en) The use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2004046309A3 (en) Methods for inhibiting viral replication in vivo
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
WO2005115360A3 (en) Formulations of anti-pain agents and methods of using the same
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
GB0020504D0 (en) Therapeutic method
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
PT1670489E (pt) Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
IL159770A0 (en) Calcium salts with cytotoxic activity
ATE371446T1 (de) Zusammensetzungen zur verhinderung der adhäsion
HK1108382A (en) Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level
UA40271U (ru) Способ комбинированного лечения токсоплазмозной инфекции у новорожденных
GEP20053485B (en) Energo-Information Disk for Improving Health of Human Organism
SE0004026D0 (sv) New use
TW200512004A (en) Methods for inhibiting viral replication in vivo